Details of the Drug Combination

General Information of Drug Combination (ID: DC88JPN)

Drug Combination Name
Wortmannin Marizomib
Indication
Disease Entry Status REF
Diffuse intrinsic pontine glioma Investigative [1]
Component Drugs Wortmannin   DM8EVK5 Marizomib   DME9QGW
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: DIPG25
Zero Interaction Potency (ZIP) Score: 5.25
Bliss Independence Score: 3.99
Loewe Additivity Score: 2.96
LHighest Single Agent (HSA) Score: 6.18

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Wortmannin
Disease Entry ICD 11 Status REF
Haematological malignancy 2B33.Y Terminated [2]
Wortmannin Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
PI3-kinase delta (PIK3CD) TTGBPJE PK3CD_HUMAN Inhibitor [7]
PI3-kinase gamma (PIK3CG) TTHBTOP PK3CG_HUMAN Inhibitor [8]
------------------------------------------------------------------------------------
Wortmannin Interacts with 40 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
G1/S-specific cyclin-D2 (CCND2) OTDULQF9 CCND2_HUMAN Increases Expression [9]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [10]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Decreases Expression [11]
Serine/threonine-protein kinase Chk1 (CHEK1) OTTTI622 CHK1_HUMAN Decreases Expression [12]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Expression [13]
Forkhead box protein O3 (FOXO3) OTHXQG4P FOXO3_HUMAN Decreases Phosphorylation [6]
Serine/threonine-protein kinase Chk2 (CHEK2) OT8ZPCNS CHK2_HUMAN Decreases Phosphorylation [14]
Insulin-like growth factor II (IGF2) OTJ4O6MW IGF2_HUMAN Decreases Response To Substance [15]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Increases Response To Substance [16]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Decreases Phosphorylation [14]
72 kDa type IV collagenase (MMP2) OT5NIWA2 MMP2_HUMAN Decreases Expression [17]
Intestinal-type alkaline phosphatase (ALPI) OTTQ468O PPBI_HUMAN Increases Activity [18]
Heat shock 70 kDa protein 1A (HSPA1A) OTKGIE76 HS71A_HUMAN Decreases Expression [19]
Cadherin-1 (CDH1) OTFJMXPM CADH1_HUMAN Increases Expression [6]
Secretogranin-2 (SCG2) OTUHXX8U SCG2_HUMAN Decreases Activity [20]
Matrix metalloproteinase-9 (MMP9) OTB2QDAV MMP9_HUMAN Decreases Activity [21]
Ribosomal protein S6 kinase beta-1 (RPS6KB1) OTAELNGX KS6B1_HUMAN Decreases Phosphorylation [22]
Tumor necrosis factor receptor superfamily member 6 (FAS) OTP9XG86 TNR6_HUMAN Affects Response To Substance [16]
Metallothionein-3 (MT3) OTVCZ7HI MT3_HUMAN Decreases Response To Substance [23]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Decreases Phosphorylation [24]
Phosphatidylinositol 3-kinase regulatory subunit alpha (PIK3R1) OT5BZ1J9 P85A_HUMAN Decreases Activity [25]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Decreases Phosphorylation [24]
Nitric oxide synthase 3 (NOS3) OTLDT7NR NOS3_HUMAN Decreases Phosphorylation [26]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Activity [27]
Catenin beta-1 (CTNNB1) OTZ932A3 CTNB1_HUMAN Decreases Expression [28]
Glucose-6-phosphatase catalytic subunit 1 (G6PC1) OTJ6FM9F G6PC1_HUMAN Increases Expression [29]
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA) OTTOMI8J PK3CA_HUMAN Decreases Activity [25]
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform (PIK3CB) OTO8JQJA PK3CB_HUMAN Decreases Activity [30]
Glycogen synthase kinase-3 beta (GSK3B) OTL3L14B GSK3B_HUMAN Decreases Phosphorylation [19]
Selenoprotein P (SELENOP) OT02B8IR SEPP1_HUMAN Increases Expression [29]
Heat shock factor protein 1 (HSF1) OTYNJ4KP HSF1_HUMAN Affects Localization [19]
Myosin regulatory light chain 2, atrial isoform (MYL7) OT7ZNDP4 MLRA_HUMAN Decreases Phosphorylation [31]
Elongation factor 1-alpha 2 (EEF1A2) OT9Z23K5 EF1A2_HUMAN Increases Expression [32]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) OT2YYI1A MCL1_HUMAN Decreases Expression [33]
Baculoviral IAP repeat-containing protein 2 (BIRC2) OTFXFREP BIRC2_HUMAN Decreases Expression [13]
Hypoxia-inducible factor 1-alpha (HIF1A) OTADSC03 HIF1A_HUMAN Decreases Expression [34]
Programmed cell death protein 4 (PDCD4) OTZ6NXUX PDCD4_HUMAN Increases Expression [35]
Krueppel-like factor 6 (KLF6) OTQY9S7F KLF6_HUMAN Decreases Expression [36]
Growth/differentiation factor 15 (GDF15) OTWQN50N GDF15_HUMAN Increases Expression [37]
Forkhead box protein P1 (FOXP1) OTSG6XGF FOXP1_HUMAN Decreases Expression [22]
------------------------------------------------------------------------------------
⏷ Show the Full List of 40 DOT(s)
Indication(s) of Marizomib
Disease Entry ICD 11 Status REF
Glioblastoma of brain 2A00.00 Phase 3 [3]
Malignant glioma 2A00.0 Phase 1 [4]
Multiple myeloma 2A83 Phase 1 [4]
Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
Marizomib Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Proteasome (PS) TTU7ZMG NOUNIPROTAC Inhibitor [38]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6060).
3 ClinicalTrials.gov (NCT03345095) A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma (MIRAGE). U.S. National Institutes of Health.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of Triphase Accelerator .
6 (-)-Liriopein B Suppresses Breast Cancer Progression via Inhibition of Multiple Kinases. Chem Res Toxicol. 2015 May 18;28(5):897-906. doi: 10.1021/tx500518j. Epub 2015 Apr 21.
7 Selective role of PI3K delta in neutrophil inflammatory responses. Biochem Biophys Res Commun. 2003 Sep 5;308(4):764-9.
8 Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. Cancer Res. 2002 Aug 15;62(16):4671-7.
9 Activation of methionine synthase by insulin-like growth factor-1 and dopamine: a target for neurodevelopmental toxins and thimerosal. Mol Psychiatry. 2004 Apr;9(4):358-70.
10 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
11 The dietary phytochemical 3,3'-diindolylmethane induces G2/M arrest and apoptosis in oral squamous cell carcinoma by modulating Akt-NF-B, MAPK, and p53 signaling. Chem Biol Interact. 2012 Feb 5;195(3):224-30.
12 H2AX, pChk1, and Wip1 as potential markers of persistent DNA damage derived from dibenzo[a,l]pyrene and PAH-containing extracts from contaminated soils. Chem Res Toxicol. 2012 Apr 16;25(4):862-72. doi: 10.1021/tx200436n. Epub 2012 Mar 22.
13 Phosphatidylinositol 3-kinase inhibition down-regulates survivin and facilitates TRAIL-mediated apoptosis in neuroblastomas. J Pediatr Surg. 2004 Apr;39(4):516-21. doi: 10.1016/j.jpedsurg.2003.12.008.
14 DNA damage responses in cells exposed to sulphur mustard. Toxicol Lett. 2012 Feb 25;209(1):1-10. doi: 10.1016/j.toxlet.2011.11.009. Epub 2011 Nov 18.
15 Induction of steroid sulfatase expression in PC-3 human prostate cancer cells by insulin-like growth factor II. Toxicol Lett. 2013 Nov 25;223(2):109-15. doi: 10.1016/j.toxlet.2013.09.006. Epub 2013 Sep 18.
16 PI3K/AKT inhibitors aggravate death receptor-mediated hepatocyte apoptosis and liver injury. Toxicol Appl Pharmacol. 2019 Oct 15;381:114729. doi: 10.1016/j.taap.2019.114729. Epub 2019 Aug 22.
17 Brazilein suppresses migration and invasion of MDA-MB-231 breast cancer cells. Chem Biol Interact. 2013 Jul 5;204(2):105-15. doi: 10.1016/j.cbi.2013.05.005. Epub 2013 May 21.
18 Methotrexate induced differentiation in colon cancer cells is primarily due to purine deprivation. J Cell Biochem. 2006 Sep 1;99(1):146-55. doi: 10.1002/jcb.20908.
19 Modulation of Akt and ERK1/2 pathways by resveratrol in chronic myelogenous leukemia (CML) cells results in the downregulation of Hsp70. PLoS One. 2010 Jan 14;5(1):e8719. doi: 10.1371/journal.pone.0008719.
20 Secretoneurin, a novel neuropeptide, is a potent chemoattractant for human eosinophils. Blood. 1998 Mar 1;91(5):1527-32.
21 Antimetastatic effect and mechanism of ovatodiolide in MDA-MB-231 human breast cancer cells. Chem Biol Interact. 2011 Nov 15;194(2-3):148-58. doi: 10.1016/j.cbi.2011.10.002. Epub 2011 Oct 19.
22 FOXP1 regulation via the PI3K/Akt/p70S6K signaling pathway in breast cancer cells. Oncol Lett. 2015 Mar;9(3):1482-1488. doi: 10.3892/ol.2015.2885. Epub 2015 Jan 16.
23 Metallothionein-III provides neuronal protection through activation of nuclear factor-kappaB via the TrkA/phosphatidylinositol-3 kinase/Akt signaling pathway. Toxicol Sci. 2009 Dec;112(2):435-49. doi: 10.1093/toxsci/kfp230. Epub 2009 Sep 18.
24 Preclinical pharmacological evaluation of a novel multiple kinase inhibitor, ON123300, in brain tumor models. Mol Cancer Ther. 2014 May;13(5):1105-16. doi: 10.1158/1535-7163.MCT-13-0847. Epub 2014 Feb 25.
25 Expression and purification of PI3 kinase alpha and development of an ATP depletion and an alphascreen PI3 kinase activity assay. J Biomol Screen. 2008 Dec;13(10):1035-40. doi: 10.1177/1087057108326079. Epub 2008 Nov 25.
26 Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC. Biochem Biophys Res Commun. 2006 Mar 24;341(4):973-8. doi: 10.1016/j.bbrc.2006.01.052. Epub 2006 Jan 24.
27 The phosphoinositide 3-kinase/AKT1 pathway involvement in drug and all-trans-retinoic acid resistance of leukemia cells. Mol Cancer Res. 2003 Jan;1(3):234-46.
28 Regulation and possible function of beta-catenin in human monocytes. J Immunol. 2001 Dec 15;167(12):6786-93. doi: 10.4049/jimmunol.167.12.6786.
29 Acute and long-term effects of arsenite in HepG2 cells: modulation of insulin signaling. Biometals. 2014 Apr;27(2):317-32. doi: 10.1007/s10534-014-9714-y. Epub 2014 Feb 18.
30 Effect of semi-synthesized quercetin water-soluble derivatives on recombinant human phosphatidylinositol 3-kinase p110beta catalytic subunit. Acta Pharmacol Sin. 2002 Apr;23(4):339-42.
31 Key role of myosin light chain (MLC) kinase-mediated MLC2a phosphorylation in the alpha 1-adrenergic positive inotropic effect in human atrium. Cardiovasc Res. 2005 Jan 1;65(1):211-20. doi: 10.1016/j.cardiores.2004.09.019.
32 eEF1A2 siRNA Suppresses MPP(+)-Induced Activation of Akt and mTOR and Potentiates Caspase-3 Activation in a Parkinson's Disease Model. ScientificWorldJournal. 2023 Apr 3;2023:1335201. doi: 10.1155/2023/1335201. eCollection 2023.
33 ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation. Biochem Pharmacol. 2013 Apr 1;85(7):927-36. doi: 10.1016/j.bcp.2013.01.011. Epub 2013 Jan 24.
34 PI3K/Akt is required for heat shock proteins to protect hypoxia-inducible factor 1alpha from pVHL-independent degradation. J Biol Chem. 2004 Apr 2;279(14):13506-13. doi: 10.1074/jbc.M310164200. Epub 2004 Jan 15.
35 Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells. Mol Cancer Res. 2007 Jan;5(1):95-108. doi: 10.1158/1541-7786.MCR-06-0125.
36 Oxidative stress modulates KLF6Full and its splice variants. Alcohol Clin Exp Res. 2012 Nov;36(11):1851-62. doi: 10.1111/j.1530-0277.2012.01798.x. Epub 2012 Apr 6.
37 Aspidin PB, a phloroglucinol derivative, induces apoptosis in human hepatocarcinoma HepG2 cells by modulating PI3K/Akt/GSK3 pathway. Chem Biol Interact. 2013 Jan 25;201(1-3):1-8. doi: 10.1016/j.cbi.2012.11.005. Epub 2012 Nov 21.
38 Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets. 2011 Mar;11(3):254-84.